Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001657312-25-000026
Filing Date
2025-08-06
Accepted
2025-08-06 08:03:14
Documents
54
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q vrna-20250630.htm   iXBRL 10-Q 1276290
2 EX-10.2 nuance-veronaxlicenseagree.htm EX-10.2 26992
3 EX-31.1 exhibit311q225.htm EX-31.1 8858
4 EX-31.2 exhibit312q225.htm EX-31.2 8895
5 EX-32.1 exhibit321q225.htm EX-32.1 5161
6 EX-32.2 exhibit322q225.htm EX-32.2 5254
12 GRAPHIC vrna-20250630_g1.jpg GRAPHIC 157409
  Complete submission text file 0001657312-25-000026.txt   5361492

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vrna-20250630.xsd EX-101.SCH 35572
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vrna-20250630_cal.xml EX-101.CAL 55849
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vrna-20250630_def.xml EX-101.DEF 141544
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vrna-20250630_lab.xml EX-101.LAB 479774
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vrna-20250630_pre.xml EX-101.PRE 301473
57 EXTRACTED XBRL INSTANCE DOCUMENT vrna-20250630_htm.xml XML 418507
Mailing Address 3 MORE LONDON RIVERSIDE LONDON X0 SE1 2RE
Business Address 3 MORE LONDON RIVERSIDE LONDON X0 SE1 2RE 011-44-0-2032834200
Verona Pharma plc (Filer) CIK: 0001657312 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38067 | Film No.: 251187555
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)